Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Augusto A Miravalle

TitleAffiliate
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-NEUR General Operations
Phone303/724-2187

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Oct; 55:103170. PMID: 34364034.
      View in: PubMed
    2. Swanson CW, Proessl F, Stephens JA, Miravalle AA, Fling BW. Non-invasive brain stimulation to assess neurophysiologic underpinnings of lower limb motor impairment in multiple sclerosis. J Neurosci Methods. 2021 05 15; 356:109143. PMID: 33757762.
      View in: PubMed
    3. Miravalle AA, Katz J, Robertson D, Hayward B, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ. CLICK-MS and MASTER-2 Phase IV?trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis. Neurodegener Dis Manag. 2021 04; 11(2):99-111. PMID: 33517769.
      View in: PubMed
    4. Rempe T, Carlson A, Miravalle A, Gyang TV. Anti-JCV antibody index does not change during ocrelizumab-treatment. Mult Scler J Exp Transl Clin. 2020 Jul-Sep; 6(3):2055217320960510. PMID: 33029356.
      View in: PubMed
    5. Rempe T, Wang Q, Wu Q, Ballur Narayana Reddy V, Newcomer Z, Miravalle A, Mao-Draayer Y. Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing. Neurol Neuroimmunol Neuroinflamm. 2020 05 04; 7(3). PMID: 32198230.
      View in: PubMed
    6. Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019; 12:1756286419837809. PMID: 30956686.
      View in: PubMed
    7. Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 02 12; 92(7):e723-e732. PMID: 30635477.
      View in: PubMed
    8. Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemp Clin Trials. 2016 09; 50:166-77. PMID: 27521810.
      View in: PubMed
    9. Korb PJ, Miravalle A. Coding in Multiple Sclerosis and Other Demyelinating Diseases. Continuum (Minneap Minn). 2016 06; 22(3):951-9. PMID: 27261692.
      View in: PubMed
    10. Harlow DE, Honce JM, Miravalle AA. Remyelination Therapy in Multiple Sclerosis. Front Neurol. 2015; 6:257. PMID: 26696956.
      View in: PubMed
    11. Liewluck T, Miravalle A. Immune-Mediated Neurological Disorders. Curr Neurol Neurosci Rep. 2015 Sep; 15(9):61. PMID: 26202897.
      View in: PubMed
    12. Miravalle AA, Schreiner T. Neurologic complications of vaccinations. Handb Clin Neurol. 2014; 121:1549-57. PMID: 24365435.
      View in: PubMed
    13. Campbell JD, Ghushchyan V, Brett McQueen R, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, Nair K. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord. 2014 Mar; 3(2):227-36. PMID: 25878010.
      View in: PubMed
    14. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012 Jul; 71(7):604-17. PMID: 22710964.
      View in: PubMed
    15. Schreiner TL, Miravalle A. Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine. J Cent Nerv Syst Dis. 2012; 4:1-14. PMID: 23650463.
      View in: PubMed
    16. Nielsen AS, Miravalle A, Langer-Gould A, Cooper J, Edwards KR, Kinkel RP. Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. Mult Scler. 2012 Mar; 18(3):377-8. PMID: 21828201.
      View in: PubMed
    17. Miravalle AA. Guidelines and best practices for appropriate use of dalfampridine in managed care populations. Am J Manag Care. 2011 May; 17 Suppl 5 Improving:S154-60. PMID: 21761954.
      View in: PubMed
    18. Kala M, Miravalle A, Vollmer T. Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol. 2011 Jun; 235(1-2):9-17. PMID: 21402415.
      View in: PubMed
    19. Miravalle A, Corboy JR. Therapeutic options in multiple sclerosis: five new things. Neurology. 2010 Nov 02; 75(18 Suppl 1):S22-7. PMID: 21041767.
      View in: PubMed
    20. Bennett JL, Miravalle AA. Recent advances in the treatment of multiple sclerosis. J Exp Pharmacol. 2010; 2:155-61. PMID: 27186101.
      View in: PubMed
    21. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011 Feb; 68(2):186-91. PMID: 20937940.
      View in: PubMed
    22. Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, Wolinsky JS, Ziemssen T. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol. 2010 Sep; 68(3):409-11. PMID: 20818795.
      View in: PubMed
    23. Corboy JR, Miravalle AA. Emerging therapies for treatment of multiple sclerosis. J Inflamm Res. 2010; 3:53-9. PMID: 22096357.
      View in: PubMed
    24. Miravalle A, Biller J, Schnitzler E, Bonwit A. Neurological complications following vaccinations. Neurol Res. 2010 Apr; 32(3):285-92. PMID: 20406607.
      View in: PubMed
    25. Miravalle A, Biller J, Silva E, Conneely M, O'Keefe P. Acute disseminated encephalomyelitis: yellow fever vaccination. Arq Neuropsiquiatr. 2009 Sep; 67(3A):710-1. PMID: 19722058.
      View in: PubMed
    26. Miravalle A, Roos KL. Encephalitis complicating smallpox vaccination. Arch Neurol. 2003 Jul; 60(7):925-8. PMID: 12873847.
      View in: PubMed
    Miravalle's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (87) concept(s)
    _
    Co-Authors Expand Description
    See all (10) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)